Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-07-04 DOI:10.1080/14796678.2024.2363673

Sana Mohsin, Misha Hasan, Zubaid Moazzam Sheikh, Fatima Mustafa, Vesna Tegeltija, Sarwan Kumar, Jai Kumar

{"title":"Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients.","authors":"Sana Mohsin, Misha Hasan, Zubaid Moazzam Sheikh, Fatima Mustafa, Vesna Tegeltija, Sarwan Kumar, Jai Kumar","doi":"10.1080/14796678.2024.2363673","DOIUrl":null,"url":null,"abstract":"Aim: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity.Methods: PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI).Results: 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); p = 0.005; I2= 32%], HF hospitalization [RR = 0.20 (0.04-1.02); p = 0.05; I2= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); p = 0.11, I2= 0%].Conclusion: SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"395-407"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457630/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2363673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity.Methods: PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI).Results: 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); p = 0.005; I²= 32%], HF hospitalization [RR = 0.20 (0.04-1.02); p = 0.05; I²= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); p = 0.11, I²= 0%].Conclusion: SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SGLT2 抑制剂对蒽环类药物引起的心脏毒性的疗效：一项针对癌症患者的荟萃分析。

目的：钠-葡萄糖共转运体-2抑制剂（SGLT2i）可降低蒽环类药物引起的心脏毒性。研究方法检索PubMed和Google Scholar上截至2023年9月有关SGLT2i治疗蒽环类药物诱发的心脏毒性的研究。研究考虑了总死亡率和心血管事件。采用随机效应模型，以95%置信区间（CI）汇总RR和HR数据。研究结果共确定了 3 项队列研究，分析了 2817 名患者。结果显示，总死亡率[RR = 0.52 (0.33-0.82)；p = 0.005；I2= 32%]、HF 住院率[RR = 0.20 (0.04-1.02)；p = 0.05；I2= 0%]明显降低，而 HF 发病率[RR = 0.50 (0.20-1.16)；p = 0.11，I2= 0%]没有明显降低。结论SGLT2i 可降低心力衰竭导致的死亡率和住院率，从而提高接受蒽环类药物治疗的癌症患者的生存机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.